设为首页|加入收藏|联系我们
主页 > 文献专区 > 正文
Role of Combination herapy in the Treatment of Hypertension: Focus on Valsartan plus Amlodipine
时间:2010-01-04 17:29    来源:未知    作者:admin     点击:

Hypertension control is rare in clinical practice, particularly in high-risk patients. A large factor is therapeutic inertia deriving from poorly prescribed lifestyle changes, excess monotherapy use, and scarce on-treatment modifications. The use of drug combinations significantly improves blood pressure (BP) control; in particular, fixed combinations improve therapy without increasing daily pill intake, thereby favouring patient compliance and therapy continuation. The most widely used fixed combination is based on thiazide diuretics added to either angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). Several large-scale clinical trials have been conducted showing that these combinations are effective in lowering BP. However, thiazide diuretics can reduce the metabolic benefits derived from renin–angiotensin–aldosterone system (RAAS) inhibitors in high metabolic risk patients. In contrast, ACE inhibitors or ARBs combined with dihydropyridine calcium channel antagonists (DHPCAs) exert a marked antihypertensive effect without decreasing metabolic protection by RAAS blockade. In the recent JIKEI heart study, ~60% of patients affected by hypertension, heart failure, coronary heart disease or their combination in the valsartan arm were simultaneously treated with DHPCAs. Of note, a 39% reduction in the primary endpoint of combined morbidity and mortality was reported in the valsartan compared with the non-valsartan arm. Furthermore, in a recent multinational study, 83% of 3161 hypertensive patients treated with valsartan and the DHCPA amlodipine reported a concontrolled BP after 8 weeks of treatment. As expected, amlodipine did not negatively influence the metabolic profile of patients, thereby supporting the role of ARB+DHPCA combinations as effective and promising tools in hypertension treatment.

 

本文来自 Adv Ther. 2008;25(4):299319


14:00-14:30
14:30-14:40
14:40-14:50
14:50-15:20


15:20-16:30


16:30-16:50

16:50-17:20
17:20-17:30
签到
欢迎辞
诺华领导致辞
强化达标的SPC策略
--从CHINA STATUS
到治疗指南
SPC Therapy-Which
is the best?

倍博特中国III期临
床研究结果
Q&A
大会总结

诸骏仁教授

王继光教授


Prof Bryan
williams
翻译:林建华教授
孙宁玲教授

葛均波教授
关于我们 | 资格证书 | 版权声明 | 论坛帮助 | 友情链接 | 联系我们
丁香园DXY.CN 版权所有Copyright(C)2000-2009 DXY All Rights Reserved. 网站备案号:浙B2-20070219(含BBS)
联系地址:杭州市滨江区泰安路239号盾安发展大厦1202室
邮政编码:310052 Tel:0571-28182600 Fax:0571-28182627 88859635 网站建设:丁香园